Tag:

Genzyme

Latest Headlines

Latest Headlines

Sanofi bags 'breakthrough' tag for new Genzyme rare disease med

Sanofi's rare disease-focused unit Genzyme picked up the FDA's coveted breakthrough-therapy designation for a drug designed to treat a form of Niemann-Pick disease.

Sanofi snags a 'breakthrough' tag for a new rare disease drug

Sanofi's rare disease-focused Genzyme picked up the FDA's coveted breakthrough-therapy designation for a candidate designed to treat a form of Niemann-Pick disease.

High-profile Huntington's disease film scores on social media, but where was pharma?

HBO premiered an award-winning short documentary about Huntington's disease, a rare, hereditary neurological malady, on Monday night. The film follows actress and filmmaker Marianne Palka as she finds out the results of her genetic test. If someone has a parent with the disease as she did, they have a 50/50 chance of getting the disease. The missing voice? Pharma.

Ablynx adds Genzyme to roster of big-name collaborators

Ablynx has entered into a collaboration with Sanofi's Genzyme to investigate the use of its single-domain antibodies against a target involved with multiple sclerosis. The deal gives Genzyme the exclusive right to test the antibodies in models relevant to multiple sclerosis.

Genzyme touts postmarket study of Cerdelga, the only first-line oral therapy for Gaucher disease

Rare disease specialist Genzyme talked up the results of a study published in  The Journal of the American Medical Association  concluding that the only first-line oral therapy for Gaucher disease reduced spleen size 28% compared to placebo after 9 months.

Genzyme biologics plant continues to pay off for Sanofi

Three years out, French drugmaker Sanofi continues to reap benefits from having opened a U.S. biologics plant that added capacity for some of the rare disease meds developed by its Genzyme unit.

Sanofi embarks on an $845M gene therapy R&D odyssey with Voyager

Sanofi subsidiary Genzyme is tying up with gene therapy upstart Voyager Therapeutics, gambling $100 million upfront on the hot field and promising up to $745 million in milestones for their partnership on a full slate of development programs.

Sanofi nears European Gaucher market shakeup with EMA recommendation

In August, Sanofi's Genzyme won the FDA's blessing to take brand-new orphan drug Cerdelga into the U.S. Gaucher disease market, where the company hoped the pill could show up older, intravenous treatments. And now, it could be on its way to the same opportunity in the EU.

FDA reverses an embarrassing rejection of Sanofi's Lemtrada, OKs MS drug

Late on Friday the FDA put out the word that it has reversed its earlier decision against Sanofi's multiple sclerosis drug Lemtrada, agreeing to allow the pharma giant the right to market the treatment--with some tight controls on just who will get this drug for the relapsing form of the disease.

Alnylam trumpets early promise for its Sanofi-partnered RNAi drug

Alnylam's in-development RNAi treatment successfully staved off nerve damage related to a rare disease in an ongoing study, the biotech said, early but promising results as the company heads into Phase III with partner Sanofi in tow.